Achieve Life Sciences Files 8-K Report
Ticker: ACHV · Form: 8-K · Filed: Feb 10, 2025 · CIK: 949858
| Field | Detail |
|---|---|
| Company | Achieve Life Sciences, Inc. (ACHV) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
Related Tickers: ACHV
TL;DR
ACHV filed an 8-K on Feb 10, 2025, covering other events and financials.
AI Summary
On February 10, 2025, Achieve Life Sciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as OncoGenex Pharmaceuticals, Inc. and Sonus Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Bothell, WA, with an additional address in Vancouver, BC, Canada.
Why It Matters
This 8-K filing provides updates on "Other Events" and "Financial Statements and Exhibits" for Achieve Life Sciences, Inc., which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to disclose any immediate, significant risks or negative developments.
Key Players & Entities
- Achieve Life Sciences, Inc. (company) — Registrant
- February 10, 2025 (date) — Date of earliest event reported
- OncoGenex Pharmaceuticals, Inc. (company) — Former company name
- Sonus Pharmaceuticals Inc (company) — Former company name
- Bothell, WA (location) — Principal Executive Offices
- Vancouver, BC, Canada (location) — Additional address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits" as of February 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 10, 2025.
What are the former names of Achieve Life Sciences, Inc.?
Achieve Life Sciences, Inc. was formerly known as OncoGenex Pharmaceuticals, Inc. and Sonus Pharmaceuticals Inc.
Where are Achieve Life Sciences, Inc.'s principal executive offices located?
Achieve Life Sciences, Inc.'s principal executive offices are located at 22722 29th Drive SE, Suite 100, Bothell, WA 98021.
What is the SIC code for Achieve Life Sciences, Inc.?
The Standard Industrial Classification (SIC) code for Achieve Life Sciences, Inc. is 2835, which pertains to "IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES."
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-10 16:10:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACHV The Nasdaq Stock Mar
Filing Documents
- achv-20250210.htm (8-K) — 52KB
- achv-ex99_1.htm (EX-99.1) — 28KB
- img9551541_0.jpg (GRAPHIC) — 14KB
- 0000950170-25-017068.txt ( ) — 256KB
- achv-20250210.xsd (EX-101.SCH) — 50KB
- achv-20250210_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On February 10, 2025, Achieve Life Sciences, Inc. (the "Company") announced that the Data Safety Monitoring Committee ("DSMC") recently completed its second independent review of the Company's ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. Following this second comprehensive review of available safety data, the DSMC stated that it did not identify any unexpected treatment-related adverse events and that the participants' adherence to their cytisinicline medication was excellent. Overall safety data remained consistent with previous findings. The DSMC concluded the study may continue as planned without any modifications.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 Press release of Achieve Life Sciences, Inc. dated February 10, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ACHIEVE LIFE SCIENCES, INC. Date: February 10, 2025 /s/ Mark Oki Mark Oki Chief Financial Officer (Principal Financial Officer)